Median Technologies: Disclosure of total number of voting rights and number of shares in the capital as of February 29th, 2024

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

Regulatory News:

Median Technologies (Paris:ALMDT):

Total number of shares

18,404,608

Number of real voting rights*

(excluding treasury shares**)

18,347,480

Theoretical number of voting rights*

(including treasury shares**)

18,381,408

(*) Class E preference shares are non-voting

(**) pursuant to article 223-11 of the AMF’s General Regulations

About Median Technologies: Pioneering in innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to elevate the accuracy of early cancer and metabolic disease diagnoses and treatments. Median's offerings, including iCRO for medical image analysis and management in oncology trials and eyonis™, AI/ML tech-based suite of software as medical devices (SaMD), empower biopharmaceutical entities and clinicians to advance patient care and expedite novel therapies. Since its inception, the French-based company, with a presence in the U.S. and China, has been recognized as an "Innovative company" by BPI France and trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information: www.mediantechnologies.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240308862631/en/

Median Technologies Emmanuelle Leygues Head of Corporate Marketing & Financial Communications [phone] [e-mail] Press - ALIZE RP Caroline Carmagnol [phone] [e-mail] Investors - ACTIFIN Ghislaine Gasparetto [phone] [e-mail]